drugset / Trial / NCT07588698
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggressive B-cell non-Hodgkin lymphoma.
Timeline
- Start
- 2026-11-15
- Primary completion
- 2028-08-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Epcoritamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Prednisolone | Other / unclassified | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Vincristine | Small molecule | — | — |